RT Journal第SR电子T1使用β阻滞剂的使用与阻塞性睡眠呼吸暂停症患者患者的白天嗜睡症的使用不相关。欧洲呼吸期刊Jo EUR Respir J FD欧洲呼吸学会SP PA4175 Do 10.1183 / 13993003.Conground-2019.Pa4175 VO188bet官网地址54是43 A1 Bikov，Andras A1 Meszaros，Martina A1 Vestbo，JørgenA1Mathioudakis，亚历山大A1 kunos，Laszlo YR 2019 UL //www.qdcxjkg.com/content/54/suppl_63/pa4175.abstract ab背景：增加白天嗜睡是β阻滞剂的已知副作用。这些药物以心血管疾病和高血压表明，经常伴随阻塞性睡眠呼吸暂停（OSA）。医生可能不愿意在心血管患者中患有Co-Morbid OSA的β-窝，而不是恶化过度的白天嗜睡。然而，在OSA之前的β阻滞剂和白天嗜睡之间的关联尚未进行。方法：我们分析了286名患者的结果，因涉嫌OSA而被睡眠实验室。我们排除了使用任何镇静药物的受试者，包括抗抑郁药，褪黑素或苯二氮卓。他们都没有得到CPAP或下颌进步装置的对待。参与者填写了欧洲呼吸嗜睡量表（ESS）并接受了医院的多核来摄影。结果：197例患者被诊断为OSA（呼吸暂停 - 低尿症指数，AHI≥5/ h）。73个受试者使用β-嵌体，包括62例OSA患者（25个Bisoprolol，21个Nebivolol，7个美托洛尔，6个Carvedilol，2 betaxolol，1个丙醇）。 ESS directly related to AHI in OSA (p=0.04, r=0.14) and total sleep time in non-OSA controls (p=0.03, r=0.31). There was no relationship between the ESS and the use of beta-blockers in OSA (p=0.22) or in controls (p=0.43). However, interestingly, bisoprolol was significantly associated with lower ESS in OSA (n=25, r=-0.15, p=0.02).Conclusions: Beta-blockers in general are not associated with excessive daytime sleepiness in OSA. However, lipophilic agents penetrating through the blood-brain barrier (i.e. propranolol or metoprolol) should be investigated separately.FootnotesCite this article as: European Respiratory Journal 2019; 54: Suppl. 63, PA4175.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).